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Abstract
Background: Despite the multiple benefits of maintaining residual urine volume (RUV) in hemodialysis (HD), there
is limited data from Sub-Saharan Africa. The aim of this study was to assess the impact of RUV decline on the
survival of HD patients.
Methods: In a retrospective cohort study, 250 consecutive chronic HD patients (mean age 52.5 years; 68.8% male,
median HD duration 6 months) from two hospitals in the city of Kinshasa were studied, between January 2007 and
July 2013. The primary outcome was lost RUV. Preserved or lost RUV was defined as decline RUV < 25 (median
decline) or ≥ 25 ml/day/month, respectively. The second endpoint was survival (time-to death). Survival curves were
built using the Kaplan-Meier methods. We used Log-rank test to compare survival curves. Predictors of mortality
were assessed by Cox proportional hazards regression models.
Results: The cumulative incidence of patients with RUV decline was 52, 4%. The median (IQR) decline in RUV was
25 (20.8–33.3) ml/day/month in the population studied, 56.7 (43.3–116.7) in patients deceased versus 12.9 (8.3–16.7)
in survivor patients (p < 0.001). Overall mortality was 78 per 1000 patient years (17 per 1000 in preserved vs 61 per
1000 lost RUV). Forty six patients (18.4%) died from withdrawal of HD due to financial constraints. The Median
survival was 17 months in the whole group while, a significant difference was shown between lost (10 months,
n = 119) vs preserved RUV group (30 months, n = 131; p = 0001). Multivariate Cox proportional hazards models
showed that, decreased RUV (adjusted HR 5.35, 95% CI [2.73–10.51], p < 0.001), financial status (aHR 2.23, [1.11–4.46],
p = 0.024), hypervolemia (a HR 2.00, [1.17–3.40], p = 0.011), lacking ACEI (aHR 2.48, [1.40–4.40], p = 0.002) or beta
blocker use (aHR 4.04, [1.42–11.54], p = 0.009), central venous catheter (aHR 6.26, [1.71–22.95], p = 0.006), serum
albumin (aHR 0.93, [0.89–0.96], p < 0.001) and hemoglobin (aHR 0.73, [0.63–0.84], p < 0.001) had emerged as the
independent predictors of all-cause mortality.
Conclusion: More than half of HD patients in this cohort study experienced fast RUV decline which contributed
substantially to increase mortality, highlighting the need for its prevention and management.
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Background
Despite advances in dialysis, mortality remains high,
especially cardiovascular. According to the record of the
2012 Annual Report of the “European Renal Association-
European Dialysis and Transplant Association, EDTA” an
overall 5-year survival of patients treated by HD in 30
European countries was 59.7%, that is 39.3% for patients
aged 65–74 years and 21.3% for those over 75 years old
[1]. In addition, the 2013 American report of “United
States Renal Data System, USRDS” stated a 5-year survival
of 40% [2]. In Japan and Taiwan, a 5-year survival was esti-
mated at 56.7% and 56% respectively [3, 4]. This high mor-
tality in the developed countries has motivated the search
and identification of potential predictors to help improv-
ing the survival of dialysis patients. This approach has the
advantage of improving individual and collective accept-
ance of dialysis and rational use of the available resources,
especially in resource-limited countries where any death
of dialysis patient could lead to a reluctance of patients to
accept this treatment.
Among the factors contributing to the improvement of
patients’ survival on dialysis, residual renal function (RRF)
or residual urine volume (RUV) appears to play a para-
mount role [5]. Indeed, several prospective, retrospective
cohorts and observational studies have shown that preser-
vation of RUV was independently associated with better
survival [5–9] and that the expected benefit was beyond the
one related to a better clearance of low molecular weight
solutes [10]. In this regard, increasing evidence suggests
that the preservation of RUV contribute in favorable way
on the predictors of mortality in HD such as hypervolemia
[11], left ventricular hypertrophy (LVH) and congestive
heart failure [12, 13], heart rhythm disorders [14] and
ischemic strokes [15]. In fact, Ma and Ding [16] found, in a
case-control study, that the frequency of LVH and systolic
dysfunction was significantly lower in patients with pre-
served RRF (RUV ≥ 200 ml/day) compared to those having
lost RRF (RUV ˂ 200 ml/day). Furthermore, similar findings
with respect to plasma concentration of B-type natriuretic
peptide (BNP) and homocysteine were also reported [16].
Despite the multiple benefits of the preservation of RUV
in patients on maintenance hemodialysis (HD), available
data on the preservation of the RUV in sub-Saharan Africa
are scarce. Hence, there is a need to fill this gap by acquir-
ing reliable data that can inform the development of policy
and rational and adapted strategies as regards extrarenal
purification to better survival of chronic HD patients. The
aim of this study was to investigate the impact of the RUV
decline on mortality in our hemodialysis patients.
Methods
In this retrospective cohort study, we selected all adults
(≥18 years old) on maintenance at least 4 weeks of renal
replacement therapy (RRT) for end-stage renal disease
(ESRD) who began HD at two existing centers in city of
Kinshasa from January 2nd, 2007 to July 31st 2013.
Data collection
Exposure
The initial RUV was directly measured at the hospital with
a 24-h urine collection. It was assessed between two ses-
sions of HD, at 3 months, 6 months, and 12 months after
the beginning of HD. Information about urine volume
was available for 250/250 (100%) participants at baseline,
200/212 (94.3%), 127/180 (70.5%) and 77/142 (54.2%) at 3,
6 and 12 months, respectively. Patients had a RUV pre-
served when its decline was lower than 25 ml/day/month
(median of decline) between initiation of HD and death or
at the end of the observation. Residual urine volume was
considered as not preserved when its decline was greater
than or equal to 25 ml/day/month.
Outcome
The primary outcome was lost RUV. The second endpoint
was survival (time-to death). Patients were followed from
the first reported date of dialysis to the date of death or
July 31st, 2013, the end of the database period. Survival,
mortality information and causes of death were obtained
from clinic report and medical records of HD patients.
Patients were divided into 2 groups according to survival
between deceased and survivor. During this study, 38
participants died in the first 3 months, 33 others in the
second quarter and 36 beyond the third quarter.
Other variables
The others parameters of interest were socio-demographic
(age, gender, occupation, marital status, socioeconomic sta-
tus, source of funding and education), clinical [height,
weight, body mass index (BMI), delay between diagnosis of
kidney disease and nephrology care or between indication
and beginning of HD, primary renal disease, complications
and comorbidities associated with ESRD on HD initiation,
medical treatment throughout follow-up in dialysis and
those specific to HD [type of vascular access, weekly time
of HD, dialysis dose (Kt/V urea index)]. All these data were
recorded on appropriate data collection form.
Funding was considered secured when financial
support in HD was provided by one of the following
facilities: company, government, foreign (mutual health
organization, social security or health insurance). Sys-
tolic blood pressure (SBP) and diastolic blood pressure
(DBP) were measured using an electronic sphygmoman-
ometer before the session of HD, pulse pressure (PP)
was defined as the difference between the SBP and DBP.
Overweight and obesity were defined by a BMI ≥ 25 kg/
m2 and ≥ 30 kg/m2 respectively [17]. Hypervolemia was
defined as a central venous pressure ≥ 13 mm Hg at the
initiation of HD [18].
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The Charlson comorbidity index was used to categorize
comorbidities as low, moderate, high and very high when
the index was ≤ 3, 4–5, 6–7 and ≥ 8, respectively [19]. In-
flammation was defined as a CRP level > 3 mg/l measured
at 3 months of HD [20].
Statistical analysis
All data were expressed as mean ± SD, median (interquar-
tile range) or number (percentage), as appropriate. Statis-
tical analyses were performed using SPSS version 21 for
Windows (SPSS Inc, Chicago, IL) and Stata version 13. The
Kaplan-Meier curves were built for survival analyses. Differ-
ences between survival curves based on the preservation or
not of RUV were described using the Log-Rank test and
the Chi-square test as appropriate. Survival was defined as
the time period between the beginning of HD and the
death or the end of the study. All patients deceased were
considered uncensored. Censored patients were those alive
(at the end of study), lost to follow up or those who were
transplanted. Risk factors for mortality were assessed by
performing univariate Cox regression analysis, and variables
with P value < 0.05 were included in a multivariate analysis
by applying a multiple Cox regression based on forward
elimination of data. The significance level of P value was
set at 0.05 or less on two-sided tests. Participants in this
study have given their consent. The personal information
had been identified and all the data were analyzed anonym-
ously. This study was approved by the Ethics Committee of
the Faculty of Medicine, University of Kinshasa (acceptance
number ESP/CE/033/2015).
Results
As shown in Table 1, 250 patients were included. At
baseline, the patients on HD were 52.5 ± 12.3 years old,
and 172 patients were male (69%). The average HD dur-
ation was 15 months. Excepted for SEL (socioeconomic
level), funding of HD, several other variables were not
different between deceased patients versus those who
survived at the end of the study. Indeed, the survivors
group had a higher socioeconomic level (p < 0.001) and
a more secure funding HD in comparison to deceased
patients (p < 0.001).
The cumulative incidence of patients with RUV de-
cline was 52, 4%. The median (IQR) RUV for all the pa-
tients before starting HD, and at 3, 6 and 12 months
were 550 (500–705), 500 (450–550), 500 (400–550) and
400 (200–530) ml/day, respectively. The median (IQR)
decline in RUV was 25 ml/day/month (20.8–33.3)
(Table 2). Compared to deceased patients, the survivors
had higher median RUV regardless the time of
observation: 840 vs 250 ml/day (p < 0.001) at initiation,
700 vs 260 ml/day (p < 0.001) after 3 months, 560 vs
250 ml/day (p < 0.001) after 6 months and 500 vs
200 ml/day (p = 0.003) after 12 months. In addition, a
lower median decline [12.9 (8.3–16.7)] was encountered
in the survivors compared with deceased patients
[56.7 (43.3–116.7) ml/day/month (p < 0.001)]. A lower
proportion of encephalopathy (37.1 vs 56.1%, p < 0.001),
hypervolemia (24.5 vs 56.1%, p < 0.001) and higher propor-
tion of AVF (30.8 vs 2.8%, p < 0.001), Diuretic (65.7 vs 36.4,
p < 0.001), ACEI (67.8 vs 38.3, p < 0.001), ßeta blocker (21.0
vs 10.3, p < 0.001), EPO (64.3 vs 38.3, p < 0.001) were also
observed in survivors patients in comparison to those who
have died.
Furthermore, the survivors had longer median HD dur-
ation (12 h vs 8 h, p = 0034), higher serum albumin (40 ±
6.9 vs 34.6 ± 8.5, p < 0.001), hemoglobin (9.2 ± 2.1 vs 7.6 ±
1.9, p < 0.001), and lower serum level of urea (205 ± 102 vs
259.9 ± 114.6, p < 0.001), creatinine (12.6 ± 6.5 vs 16.3 ±
10.2, p = 0.001), potassium (4.9 ± 1.2 vs 7.6 ± 1.9, p = 0.001),
CRP (9.1 ± 12.2 vs 34 ± 31.7, p ˂ 0.001) and lower Charlson
index (3.3 ± 1.9 vs 4.3 ± 3.1, p = 0.003) than the group of de-
ceased patients.
During the follow-up period, 143 (57.2%) patients sur-
vived, 17 (6.8%) were transplanted and 123 (49.2%)
others still continue on maintenance HD. Three patients
(1.2%) were lost to follow-up. One hundred and seven
patients (42.8%) died, representing a mortality of 78 per
1000 patient-years, with a significant difference between
persons who had preserved RUV (17 per 1000 patient-
years) versus lost RUV (61 per 1000 patient-years). The
first quarter of HD duration was the critical time to
death. The main causes of death were the following:
withdrawal from dialysis due to financial constraints
(42.9%), infectious complications (17.7%), cardiovascular
complications (15.8%), hyperkalemia (9.3%), neoplasia
(9.3%), hemodynamic instability (1.8%) and nutritional
depletion (0.9%). Table 3 compares the characteristics of
deceased patients according to withdrawal from dialysis
status. Between the both groups, there were significant
differences in SEL, financing, EPO and weekly hours of
HD. The withdrawal group had no patient with a high
SEL (0 vs 13.1%, p = 0.005), unsecured financing (93.5 vs
67.2%, p = 0.001), not EPO (80.4 vs 52.5%, p =0.002) and
had lower weekly hours of HD (69.6 vs 49.2%, p = 0.021)
than other deceased.
The Kaplan-Meier survival curve of initial HD can be
viewed in Fig. 1. The median survival of the entire group
was 17 months (Fig. 1). The cumulative survival rate of
HD patients in this cohort study was 84.8% at 3 months,
71.6% at 6 months, 62.8% at one year, 58.4% at two
years, 57.6% at three years and 57.2% at four years.
The Kaplan-Meier survival curves for preserved RUV
and lost RUV are shown in Fig. 2. For the preserved
RUV group, median follow-up time alive on dialysis was
30 months, and for lost RUV group 10 months. The
differences in survival between preserved and lost RUV
HD patients were significant (Log-rank: p < 0.001).
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Based on a multivariate Cox regression analysis per-
formed to estimate the risk factors for all-cause mortality in
HD patients, adjusted survival rates of high decline versus
low decline HD patients was significantly different (adjusted
hazard ratio [aHR] 5.35, 95% CI [2.73–10.51], p < 0.001)
(Table 4). Compared to patients having preserved RUV, the
loss of RUV group increased nearly 5 times the risk of mor-
tality. There were several others factors independently asso-
ciated with mortality. Patients without secured financing
had higher mortality rate (aHR 2.23, [1.11–4.46], p = 0.024)
than those who had secured financing patients. Further-
more, patients with hypervolemia (aHR 2.00,95% CI
[1.17–3.40], p = 0.011), catheter vs AVF (aHR 6.26, 95% CI
[1.71–22.85], p = 0.006), lower serum albumin (aHR 0.93,
95% CI [0.89–0.96], p < 0.001) hemoglobin (aHR 0.73, 95%
CI [0.63–0.84], p < 0.001) and lack of oral medication such
as ACEI (aHR 2.48, 95% CI [1.40–4.40], p = 0.002) and Beta
blocker (aHR 4.04, 95% CI [1.42–11.54], p = 0.009) had a
significantly higher mortality.
Discussion
This work evaluated the benefit of RUV on the survival
of chronic hemodialysis patients in Kinshasa, a large city
in Sub-saharan Africa.
In this present cohort study, we found a mortality rate of
HD patients of 78 per 1000 patient-years. The median
Table 1 Baseline Sociodemographic Characteristics of deceased and survivor patients
Variables All Group (N = 250) deceased (N = 107) survivor (N = 143) p
Gender, n (%) 0084
Male 172 (68.8) 71 (66.4) 101 (70.6)
Female 78 (31.2) 36 (33.6) 42 (29.4)
Mean age, years 52.5 ± 12.3 52.5 ± 13.2 52.4 ± 11.8 0.982
Marital Status, n (%) 0.602
Married 178 (71.2) 71 (66.4) 107 (74.8)
Single 72 (28.8) 36 (33.6) 36 (25.2)
Profession, n (%) 0.157
Unemployed 62 (24.8) 27 (25.2) 35 (24.5)
Student 10 (4) 7 (6.5) 3 (2.1)
Housewife 13 (5.2) 5 (4.7) 8 (5.6)
Retired 19 (7.6) 12 (11.2) 7 (4.9)
Worker 88 (35.2) 37 (34.6) 51 (35.7)
Executive 58 (23.2) 19 (17.8) 39 (27.2)
Education, n (%) 0.622
None 2 (0.8) 1 (0.9) 1 (0.7)
Primary 24 (9.6) 11 (10.3) 13 (9.1)
Secondary 88 (35.2) 43 (40.2) 45 (31.5)
Superior 136 (54.4) 52 (48.6) 84 (58.7)
SEL, n (%) <0.001
Medium 204 (81.6) 99 (92.5) 105 (73.4)
High 46 (18.4) 8 (7.5) 38 (26.6)
Financing, n (%) <0.001
Patient 49 (19.6) 19 (17.8) 30 (20.9)
Family 98 (39.2) 59 (55.1) 39 (27.3)
Firm 68 (27.2) 24 (22.4) 44 (30.8)
State 14 (5.6) 3 (2.8) 11 (7.7)
Insurance/Mutual Health Organization 21 (8.4) 2 (1.9) 19 (13.3)
Delay diagnosis-nephrology care*(days), n = 215 29 (28–30) 30 (29–30) 27 (26–29) 0.922
Delay indication - start HD* (days), n = 231 28 (27–30) 29 (28–30) 27 (21–30) 0.239
Data are expressed as numbers and proportions in parentheses or mean ± standard deviation, median (interquartile range) as appropriate
Abbreviations: SEL: socio-economic level, HD: hemodialysis
*continuous (quantitative) variables
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Table 2 Clinical and biological characteristics of deceased and survivors patients
Variables All Group (N = 250) deceased (N = 107) survivor (N = 143) p
Weight (Kg)*, n = 240 69.9 ± 13.9 67.3 ± 14.2 71.8 ± 13.5 0.012
BMI (Kg/m2)*, n = 130 24.9 ± 4.8 24.5 ± 4.2 25.1 ± 5.1 0.485
SBP, mm Hg, n = 250 153 ± 27.2 154 ± 26.4 153 ± 27.9 0.967
DBP, mm Hg, n = 250 84.7 ± 18.3 86 ± 17.4 83.6 ± 18.9 0.311
PP, mm Hg, n = 250 69.1 ± 20.7 67 ± 19.4 70 ± 21.6 0.231
Primary renal disease, n (%) 0.509
Glomerulonephritis 74 (29.5) 35 (32.7) 39 (27.3)
Diabetic nephropathy 79 (31.6) 34 (31.8) 45 (31.5)
Hypertensive nephropathy 64 (25.6) 24 (22.4) 40 (27.9)
HIVAN 10 (4) 4 (3.7) 6 (4.2)
All other 23 (9.2) 10 (9.3) 13 (9.1)
IUV (ml/day)*, n = 250 550 (500–705) 250 (200–400) 840 (750–1000) <0.001
RUV 3 months (ml/day)*, n = 200 500 (450–550) 260 (199–330) 700 (580–783) < 0.001
RUV 6 months (ml/day)*, n = 127 500 (400–550) 250 (150–350) 560 (500–750) < 0.001
RUV 12 months (ml/day)*, n = 77 400 (200–530) 200 (0–300) 500 (290–750) 0.003
Decline RUV (ml/day/month)*, n = 248 25 (20.8–33.3) 56.7 (43.3–116.7) 12.9 (8.3–16.7) <0.001
Uremic encephalopathy, n (%) 113 (45.2) 60 (56.1) 53 (37.1) 0.001
Hypervolemia, n (%) 95 (38) 60 (56.1) 35 (24.5) < 0.001
Diuretic, n (%) 133 (53.2) 39 (36.4) 94 (65.7) < 0.001
ACE inhibitor, n (%) 138 (55.2) 41 (38.3) 97 (67.8) < 0.001
Beta blocker, n (%) 41 (16.4) 11 (10.3) 30 (21.0) 0.011
EPO, n (%) 129 (51.6) 37 (34.6) 92 (64.3) < 0.001
Vascular access, n (%) < 0.001
catheter 203 (81.2) 104 (97.2) 99 (69.2)
AVF 47 (18.8) 3 (2.8) 44 (30.8)
Weekly hours of HD, n (%) 0.036
≤ 8 134 (53.6) 63 (58.9) 71 (49.7)
≥ 12 116 (46.4) 44 (41.1) 72 (50.3)
Weekly hours of HD* 8 (8–12) 8 (8–12) 12 (8–12) 0.034
Kt/V urea*, n = 133 1.3 ± 0.2 1.2 ± 0.2 1.3 ± 0.2 0.249
Charlson index*, n = 250 3.8 ± 2.6 4.3 ± 3.1 3.3 ± 1.9 0.003
Serum creatinine* (mg/dl), n = 240 16.3 ± 12.6 16.3 ± 10.2 12.6 ± 6.5 0.001
Urea *(mg/dl), n = 239 227.8 ± 110.7 259.9 ± 114.6 205 ± 102.2 < 0.001
Kaliemia*(mEq/l), n = 239 5.1 ± 1.4 5.4 ± 1.5 4.9 ± 1.2 0.001
Serum calcium* (mEq/l), n = 205 4.4 ± 0.7 4.3 ± 0.8 4.5 ± 0.6 0.119
Serum phosphate* (mg/dl), n = 91 4.9 ± 2.1 5.7 ± 2.1 4.7 ± 2.1 0.074
Serum albumine* (g/l), n = 215 37.6 ± 8.1 34.6 ± 8.5 40 ± 6.9 < 0.001
Hemoglobin* (g/dl), n = 249 8.5 ± 2.2 7.6 ± 1.9 9.2 ± 2.1 < 0.001
Hematocrit* (%), n = 247 25.8 ± 6.5 23.4 ± 5.9 27.5 ± 6.4 < 0.001
CRP* (mg/l), n = 86 14.3 ± 20.5 34 ± 31.7 9,1 ± 12.2 < 0.001
Clinical and laboratory data were collected firstly at the initiation of HD, excluding RUV at 3, 6 and 12 months after HD. Data are expressed as numbers and
proportions in parentheses or mean ± standard deviation, median (interquartile range) as appropriate
Abbreviations: BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, PP: pulse pressure, HIVAN: human Immunodeficiency virus
associated nephropathy, IRUV: initial residual urine volume, RUV: residual urine volume, ACE: angiotensin conversion enzyme inhibitor, EPO: erythropoietin, AVF:
arterio-venous fistula, Kt/V urea: clearance of urea ml/min based on the volume of distribution, HD: hemodialysis, CRP: C reactive protein
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survival was 17 months and the survival over the time was
poor during the first two years compared to that yielded in
developed countries before it stabilized at the third year or
more, at the same level or above the survival level in the
West [1, 3, 4, 21]. Lack of healthcare financing could
explain the poor survival during the first two years. As ex-
pected, treatment discontinuation due to financial con-
straints was the primary cause of mortality in chronic HD
Congolese patients. Only patients having secured financing
HD continue the treatment beyond. Indeed, the financial
situation in the DRC in 2013 showed that 80% of the urban
population was poorwith a per capita GNP barely above
100 USD [22]. Considering that a single dialysis session
costs at least 250 USD and that patients or families must
pay all this cost in the absence of government funding or
health insurance to cover the high costs of such treatment,
it becomes clear that long-term dialysis will not an option
for most Congolese with ESRD.. The cost estimates do not
include the cost of drugs like erythropoietin, iron therapy,
vitamin D analogues, antihypertensive etc., now considered
an essential part of CKD management. These drugs raise
the RRT costs by over 100% and are the exclusive preserve
of the rich. Another prominent missing factor is the cost of
AVFmaking, patient hospitalizations as well the cost of
transport to and from HD center. Ultimately, the situation
becomes untenable and the patient eventually stop dialysis
and inexorably progress to death. Furthermore, the aging
of patients in the West and in Japan combined with the
presence of several comorbidities could explain the low
survival encountered 5 years after initiation of dialysis in
these countries. One study showed that mortality was 45
times lower among African Americans than Caucasians
due to -among other reasons- the young age of African
American patients [23].
Table 3 Characteristics of patients who died by withdrawal from dialysis of financial constraints compared to patients who died
from other causes
Variables Patients died by withdrawal from HD (n = 46) Other causes of mortality (n = 61) p
Gender, n (%) 0.093
Male 33 (71.7) 38 (62.3)
Female 13 (28.3) 23 (37.7)
Mean Age, years 50.7 ± 13.3 53.7 ± 13.1 0.260
Profession, n (%) 0.261
Unemployed 25 (54.3) 26 (42.6)
Employed 21 (45.7) 35 (57.4)
SEL, n (%) 0.005
Low 16 (34.8) 10 (16.4)
Medium 30 (65.2) 43 (70.5)
High - 8 (13.1)
Financing, n (%) 0.001
Not secured 43 (93.5) 41 (67.2)
secured 3 (6.5) 20 (32.8)
EPO 0.002
No 37 (80.4) 32 (52.5)
Yes 9 (19.6) 29 (47.5)
Vascular access, n (%)
catheter 46 (100) 58 (95.1) 0.177
AVF - 3 (4.9)
IRUV* (ml/day)*, n = 250 240 (150–400) 290 (200–400) 0.939
Decline RUV* (ml/day/month), n = 248 66.7 (33.3–150) 50.8 (33.3–116.7) 0.693
Weekly hours of HD, n (%) 0.021
≤8 32 (69,6) 30 (49.2)
≥12 14 (30,4) 31 (50.8)
Duration in HD* (month) 4 (3–5) 4,5 (4–6) 0.180
Data are expressed as numbers and proportions in parentheses or mean ± standard deviation, median (interquartile range) as appropriate
Abbreviations: SEL: socio-economic level, HD: hemodialysis, EPO: erythropoietin, IRUV: initial residual urine volume, RUV: residual urine volume
*,quantitative variables
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This study showed that patients with preserved RUV
had better survival in HD. These results corroborate
those of several studies worldwide that have shown that
the conservation of RUV is a better survival factor in
HD [6–8, 10, 24–31]. Several mechanisms underlie the
benefit of preserved RUV on survival. These include
increased clearance of molecules of medium molecular
weight, effective elimination of uremic toxins, mainten-
ance of normovolemia, better control of blood pressure,
prevention or regression of LVH, better control of phos-
phorous and calcium metabolism, decrease of malnutri-
tion and inflammation and improvement of anemia [26].
The loss of residual urine volume, financing not se-
cured of HD, hypervolemia, not taking ACE inhibitor
and betablocker, central line catheter as a vascular access
normal serum albumin levels and anemia have emerged
as the main independent predictors of all-cause
mortality in this study. This observation corroborates
Fig. 1 Survival Curves global of chronic hemodialysis patients
Fig. 2 Survival Curves of chronic hemodialysis patients based on the decline residual urine volume
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that reported by other studies that have found a link
between these risk factors and mortality in chronic HD
patients [30, 32–38].
In this study, a fast RVU decline retained in the dialy-
sis fell almost 5 times the risk of death. The RRF was
chosen as independent factor of mortality in The
Netherlands Cooperative Study on the Adequacy of
Dialysis (NECOSAD) -a prospective study conducted in
the Netherlands [33], in a longitudinal cohort study of
6538 patients by Obi et al. in USA [5] and in other study
conducted in China by Lo et al. [32].
Similarly, the hypervolemia is associated with high
mortality in HD patients. Indeed, there is a close rela-
tionship between hypervolemia, pulse pressure, hyper-
trophy of left ventricle and fibroblast growth factor-23
(FGF-23) that are factors of morbidity and cardiovascu-
lar mortality in HD by contributing to atherosclerosis
and vascular calcifications. It is noticeable that both
hypervolemia and serum level of FGF-23 increase in case
of the loss of RUV [11, 34–38].
Wu et al. examining 133,564 dialysis patients aged
≥18 years old concluded that overall mortality was sig-
nificantly lower in dialysis patients who used an ACE in-
hibitor [39]. This is corroborated by the present study.
The benefit of beta-blocker in the survival of HD patients
is demonstrated by a large retrospective study involving
50,468 US hemodialysis who concluded that only the use of
beta-blocker increases from one year patient survival com-
pared with ACE inhibitor and ARBs and calcium channel
blockers [40]. In the present study, the use of beta blocker
decreased by almost 4 times the risk of death.
This study found that patients with catheter had six
times more likely to die than those with an arterioven-
ous fistula. It was reported that the catheter contributed
to mortality in HD through not only infectious compli-
cations but also the associated cardiovascular risk espe-
cially in the first 3 months after initiation of HD [41].
It is established that hypoalbuminemia predicts mor-
tality of dialysis patients and results from malnutrition
of whomit is the ultimate biological expression. Its detri-
mental role in survival in HD is supported by numerous
studies [42, 43].
In the present cohort, the mean Hb was low at 8.5 g/dl
at admission and Hb level was an independent predictor
of mortality in HD. Jung et al. in a multicenter prospective
observational study report that a Hb level < 9 g/dl multiply
by 4 the all-cause mortality in HD [44].
The unsecured financing HD was found to be inde-
pendent predictors of mortality and each multiplied by 2
the risk of death. This factor contribute to high mortality
the first months of HD observed in this study where 46
patients died by withdrawal from dialysis due to financial
constraints. The discontinuation of treatment because of
financial constraints which raises the thorny issue of
healthcare financing faced by almost all countries in
Sub-Saharan Africa and calls for more responsibility
from political and health authorities to reform the health
system [45, 46].
The interpretation of the results of this study should
consider some limitations. Its retrospective character has
not allowed to obtain all data related to the parameters
of interest. The accuracy of the 24-h urine collection
could not be established due to lack of a measured value
for urinary creatinine. The use of residual urine volume,
not direct measures including renal urea clearance and/
or creatinine clearance, is another limitation. The infor-
mation related to the reference time are indeed very im-
precise. However, there were no statistically significant
Table 4 Mortality Predictors of hemodialysis patients in Kinshasa, with Cox regression
Variables Univariate Analysis Multivariate Analysis
HR 95,0%CI p Adjusted HR 95,0%CI p
Financing (not secured vs yes) 3.33 2.16 5.15 <0.001 2.23 1.11 4.46 0.024
Weight *(Kg) 0.98 0.96 0.99 0.005 1.02 0.99 1.04 0.179
Decline RUV (≥25 vs <25 ml/day/month) 4.56 2.87 7.23 <0.001 5.35 2.73 10.51 <0.001
Hypervolemia (yes vs no) 2.79 1.90 4.09 <0.001 2.00 1.17 3.40 0.011
ACE inhibitor 2.53 1.71 3.74 <0.001 2.48 1.40 4.40 0.002
Beta blocker 2.56 1.37 4.79 0.003 4.04 1.42 11.54 0.009
Catheter vs AVF 18.84 5.89 60.26 <0.001 6.26 1.71 22.85 0.006
Weekly hours of HD ≤8 vs ≥12 1.56 1.06 2.31 0.024 1.70 0.91 3.17 0.095
Charlson Index* 1.08 1.01 1.15 0.022 1.01 0.94 1.09 0.812
Kaliemia*, mEq/l 1.17 1.02 1.35 0.027 1.12 0.92 1.35 0.272
Serum albumine*, g/l 0.94 0.92 0.97 <0.001 0.93 0.89 0.96 <0.001
Hemoglobin*, g/dl 0.731 0.66 0.81 <0.001 0.73 0.63 0.84 <0.001
Abbreviations: RUV: residual urine volume, ACE: angiotensin conversion enzyme inhibitor, AVF: arterio-venous fistula
*,quantitative variable
Mokoli et al. BMC Nephrology  (2016) 17:182 Page 8 of 10
difference between the survivor group and the deceased
in relation to these parameters, but it is known that the
late reference to the nephrologist is a poor prognostic
factor for survival in dialysis. There is also a real selec-
tion bias. Patients who can afford hemodialysis belong
either to a medium or high socioeconomic level, which
is far from the majority of patients with ESRD whose so-
cial level economic is rather low and does not even have
the ability to attend Nephrology center. Moreover, this
study has a specific distribution of cause of death; the
most frequent cause of death was withdrawal from
dialysis because of financial constraints, which is rarely
observed in developed countries. Therefore, the results
of this study cannot be extrapolated to the other areas
where health insurance well covers dialysis treatment.
Nevertheless, this study has the advantage of being the
first one in the country to determine the impact of the
preserved RUV on the survival in HD even in a context
of bad financial position.
Conclusion
The median survival of hemodialysis patients in Kinshasa
was relatively high in case of preservation of the RUV.
The loss of the RUV in HD was an independent predictor
of all-cause of mortality, in parallel with the unsecured
financing HD, hypervolemia, anemia, absence of ACE
inhibitor or betablocker, presence of catheter as a vascular
access and hypoalbuminemia. This is a good reason to
elucidate the predictors of preserving RUV for better
support for HD patients in our communities.
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